England’s health service is stepping up recruitment of doctors from overseas in order to fill a huge shortage in primary care – with European Union countries being the main target.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh